Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for non-alcoholic fatty liver disease in patients with type 2 diabetes
IRCT20250316065096N1Phase 3Completed
- Sponsor
- Qom University of Medical Sciences
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) comparing Empagliflozin plus standard treatment with Placebo plus standard treatment (2 arms). Primary endpoints: Degree of fatty liver by FibroScan and Liver fibrosis by FibroScan. Started May 2025; status: completed.
02
Drugs
empagliflozin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on IRCT20250316065096N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250316065096N1.